Literature DB >> 30056183

Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance.

Okeefe L Simmons1, Yuan Feng2, Neehar D Parikh2, Amit G Singal3.   

Abstract

BACKGROUND & AIMS: Low rates of hepatocellular carcinoma (HCC) surveillance are primarily due to provider-related process failures. However, few studies have evaluated primary care provider (PCP) practice patterns, attitudes, and barriers to HCC surveillance at academic tertiary care referral centers.
METHODS: We conducted a web-based survey of PCPs at 2 tertiary care referral centers (133 providers) from June 2017 through December 2017. The survey was adapted from pretested surveys and included questions about practice patterns, attitudes, and barriers to HCC surveillance. We used the Fisher exact and Mann-Whitney rank-sum tests to identify factors associated with adherence to HCC surveillance recommendations, for categoric and continuous variables, respectively.
RESULTS: We obtained a provider-level response rate of 75% and clinic-level response rate of 100% (133 providers). Whereas most PCPs performed HCC surveillance themselves, one-third deferred surveillance to subspecialists and referred patients to a hepatology clinic. Providers believed the combination of ultrasound and α-fetoprotein analysis to be highly effective for early stage tumor detection and reported using the combination for assessment of most patients. However, PCPs were more likely to use computed tomography- or magnetic resonance imaging-based surveillance for patients with nonalcoholic steatohepatitis or decompensated cirrhosis. Most providers believed HCC surveillance to be efficacious for early tumor detection and increasing survival. However, they desired increased high-quality evidence to characterize screening benefits and harms. Providers expressed notable misconceptions about HCC surveillance, including the role for measurement of liver enzyme levels in HCC surveillance and cost effectiveness of surveillance in patients without cirrhosis. They also reported barriers, including not being up to date on HCC surveillance recommendations, limited time in the clinic, and competing clinical concerns.
CONCLUSIONS: In a web-based survey, PCPs reported misconceptions and barriers to HCC surveillance. This indicates the need for interventions, including provider education, to improve HCC surveillance effectiveness in clinical practice.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Early Detection; Liver Cancer; NASH; Screening; Survey

Mesh:

Year:  2018        PMID: 30056183      PMCID: PMC7212522          DOI: 10.1016/j.cgh.2018.07.029

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  35 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

4.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

5.  Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System.

Authors:  Amit G Singal; Jasmin Tiro; Xilong Li; Beverley Adams-Huet; Jessica Chubak
Journal:  J Clin Gastroenterol       Date:  2017-08       Impact factor: 3.062

6.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

7.  Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.

Authors:  O Simmons; D T Fetzer; T Yokoo; J A Marrero; A Yopp; Y Kono; N D Parikh; T Browning; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2016-11-08       Impact factor: 8.171

8.  Failure rates in the hepatocellular carcinoma surveillance process.

Authors:  Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

9.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

Review 10.  Hepatocellular carcinoma in elderly patients: challenges and solutions.

Authors:  Angélique Brunot; Samuel Le Sourd; Marc Pracht; Julien Edeline
Journal:  J Hepatocell Carcinoma       Date:  2016-06-17
View more
  24 in total

1.  Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma.

Authors:  Steve Scaglione; William Adams; Allyce Caines; Pauline Devlin; Sahil Mittal; Amit G Singal; Neehar D Parikh
Journal:  Dig Dis Sci       Date:  2019-10-23       Impact factor: 3.199

2.  Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein.

Authors:  Edoardo G Giannini; Franco Trevisani
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

Review 3.  Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies.

Authors:  N Merchante; M Rodríguez-Fernández; J A Pineda
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

4.  Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.

Authors:  Nicole E Rich; Ju Dong Yang; Ponni V Perumalswami; Naim Alkhouri; Whitney Jackson; Neehar D Parikh; Neil Mehta; Reena Salgia; Andres Duarte-Rojo; Laura Kulik; Mina Rakoski; Adnan Said; Omobonike Oloruntoba; George N Ioannou; Maarouf A Hoteit; Andrew M Moon; Amol S Rangnekar; Sheila L Eswaran; Elizabeth Zheng; Janice H Jou; James Hanje; Anjana Pillai; Ruben Hernaez; Robert Wong; Steven Scaglione; Hrishikesh Samant; Devika Kapuria; Shaun Chandna; Russell Rosenblatt; Veeral Ajmera; Catherine T Frenette; Sanjaya K Satapathy; Parvez Mantry; Prasun Jalal; Binu V John; Oren K Fix; Michael Leise; Christina C Lindenmeyer; Avegail Flores; Nayan Patel; Z Gordon Jiang; Nyan Latt; Renumathy Dhanasekaran; Mobolaji Odewole; Sofia Kagan; Jorge A Marrero; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-26       Impact factor: 11.382

Review 5.  Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.

Authors:  Fasiha Kanwal; Amit G Singal
Journal:  Gastroenterology       Date:  2019-04-12       Impact factor: 22.682

Review 6.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

7.  Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.

Authors:  Joshua P Kronenfeld; Emily L Ryon; David Goldberg; Rachel M Lee; Adam Yopp; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Maria C Russell; Alan S Livingstone; Nipun B Merchant; Neha Goel
Journal:  Ann Surg Oncol       Date:  2020-09-25       Impact factor: 5.344

Review 8.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

9.  Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.

Authors:  Nicole J Kim; Karine Rozenberg-Ben-Dror; David A Jacob; Nicole E Rich; Amit G Singal; Elizabeth S Aby; Ju Dong Yang; Veronica Nguyen; Anjana Pillai; Michael Fuchs; Andrew M Moon; Hersh Shroff; Parul D Agarwal; Ponni Perumalswami; Shaun Chandna; Kali Zhou; Yuval A Patel; Nyan L Latt; Robert Wong; Andres Duarte-Rojo; Christina C Lindenmeyer; Catherine Frenette; Jin Ge; Neil Mehta; Francis Yao; Jihane N Benhammou; Patricia P Bloom; Michael Leise; Hyun-Seok Kim; Cynthia Levy; Abbey Barnard; Mandana Khalili; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-12       Impact factor: 11.382

Review 10.  Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.

Authors:  Amit G Singal; Anna S Lok; Ziding Feng; Fasiha Kanwal; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-19       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.